Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-8 of 8 for your search:
Drug:
GM2-KLH vaccine
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
E-1694
, CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9
2.
Phase III Randomized Study of Postoperative GM2-KLH and QS21 Vaccination Versus Observation in Patients With Primary Cutaneous Stage II Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
EORTC-18961
, BMS-CA152-003, NCT00005052
3.
Phase II Pilot Study of Booster Vaccinations with GM2-KLH plus QS21 for Stage III/IV Melanoma (Summary Last Modified 03/95)
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
any age
Sponsor:
Protocol IDs:
MSKCC-94009A1
, NCI-V94-0458
4.
Phase II Pilot Study of Vaccination with GM2-KLH plus QS21 in Stage III/IV Melanoma (Summary Last Modified 06/95)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
no age specified
Sponsor:
NCI
Protocol IDs:
MSKCC-94041
, NCI-H94-0471
5.
Phase II Randomized Study of Vaccination with GM-2 Ganglioside Conjugated to Keyhole Limpet Hemocyanin plus the Immunologic Adjuvant QS21 with vs without High-Dose Interferon alfa in High-Risk Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
E-2696
, E2696
6.
Phase II Pilot Study of Vaccination with GM2 Covalently Attached to KLH plus the Immunological Adjuvant QS21 in Patients with Resected Stage III/IV Melanoma (Summary Last Modified 05/92)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
any age
Sponsor:
Protocol IDs:
MSKCC-91071
, NCI-V91-0179
7.
Phase I Study of GM2-KLH Vaccine Plus the Immunological Adjuvant QS21 for Prostate Cancer (Summary Last Modified 06/98)
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-97097
, NCI-G97-1340
8.
Phase I Study of GM2-KLH Vaccine Plus the Immunological Adjuvant QS21 for High Risk Breast Cancer Patients Lacking Identifiable Disease (Summary Last Modified 06/2000)
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-97123
, NCI-H98-0015, NCT00003357
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute